Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2018
At a glance
- Drugs Levetiracetam (Primary)
- Indications Alzheimer's disease; Cognition disorders; Epilepsy
- Focus Therapeutic Use
- Acronyms LEV in AD
- 29 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 29 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 29 Jan 2018 Status changed from recruiting to active, no longer recruiting.